Efficacy, Tolerability, and Safety of Concentrated Intranasal Midazolam Spray as Emergency Medication in Epilepsy Patients During Video-EEG Monitoring

ConclusionWe conclude that in-MDZ is a safe and efficient treatment option to prevent short-term recurrence of seizures.  In-MDZ can be administered very quickly by trained staff within 1–2 min after seizure onset. No major cardiocirculatory or respiratory adverse events were observed.

Source: CNS Drugs - March 25, 2020 Category: Neurology Source Type: research